492 related articles for article (PubMed ID: 27178742)
1. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
[TBL] [Abstract][Full Text] [Related]
2. [Identification and significance of myeloid-derived suppressor cells in peripheral blood of breast cancer patients].
Wang CQ; Wei G; Xu GY; Wang JM; Bian J; Ma MS; Wang W; Xu D; Zhou ZJ; Zhao DD; Li H
Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):118-23. PubMed ID: 26899331
[TBL] [Abstract][Full Text] [Related]
3. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
4. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
[TBL] [Abstract][Full Text] [Related]
6. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
7. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
8. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Meyer C; Cagnon L; Costa-Nunes CM; Baumgaertner P; Montandon N; Leyvraz L; Michielin O; Romano E; Speiser DE
Cancer Immunol Immunother; 2014 Mar; 63(3):247-57. PubMed ID: 24357148
[TBL] [Abstract][Full Text] [Related]
9. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
10. CD33
Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
[TBL] [Abstract][Full Text] [Related]
11. IFN-γ decreased the suppressive function of CD33
Zhan X; Hu S; Wu Y; Li M; Liu T; Ming S; Wu M; Liu M; Huang X
Mol Immunol; 2018 Feb; 94():107-120. PubMed ID: 29291452
[TBL] [Abstract][Full Text] [Related]
12. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
13. Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer.
Tian T; Gu X; Zhang B; Liu Y; Yuan C; Shao L; Guo Y; Fan K
Cancer Biomark; 2015; 15(4):425-32. PubMed ID: 25792471
[TBL] [Abstract][Full Text] [Related]
14. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
15. [Expression of myeloid-derived suppressor cells in the peripheral blood and its clinical significance in renal carcinoma].
Feng S; Liu C; Zheng S; Huang P; Chen B; Guo K
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):550-3. PubMed ID: 23644118
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive role of CD11b
Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
Jordan KR; Amaria RN; Ramirez O; Callihan EB; Gao D; Borakove M; Manthey E; Borges VF; McCarter MD
Cancer Immunol Immunother; 2013 Nov; 62(11):1711-22. PubMed ID: 24072401
[TBL] [Abstract][Full Text] [Related]
18. [The number of myeloid-derived suppressor cells in the peripheral blood and tumor tissues in patients with gastric cancer and its clinical significance].
Xia R; Wang F; Gao T; Wen W; Lu B; Zhu Y; Zhang X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):740-3. PubMed ID: 25001941
[TBL] [Abstract][Full Text] [Related]
19. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
Tarhini AA; Edington H; Butterfield LH; Lin Y; Shuai Y; Tawbi H; Sander C; Yin Y; Holtzman M; Johnson J; Rao UN; Kirkwood JM
PLoS One; 2014; 9(2):e87705. PubMed ID: 24498358
[TBL] [Abstract][Full Text] [Related]
20. IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS.
Salem ML; Zidan AA; Attia M; El-Naggar RE; Nassef M; Abou El-Azm AR; El-Bate H; Yussif M; Galal S; Abo Senna M; El Demellawy M
Immunopharmacol Immunotoxicol; 2017 Aug; 39(4):188-198. PubMed ID: 28472907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
